Product Description
DFN-15, a novel oral liquid formulation of celecoxib, is being developed for the acute treatment of migraine with or without aura. Based on a faster rate of absorption and increased bioavailability, DFN-15 is being evaluated as an abortive medication for acute treatment in patients with migraine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28748412/)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dr. Reddy's Laboratories
Company Location: HYDERABAD K7 500-034
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Headache Disorders|Migraine Disorders
Phase 2: Acute Pain|Migraine Disorders|Migraine with Aura|Hyperalgesia|Migraine without Aura|Headache Disorders
Phase 1: Migraine Disorders|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| DFN-15-CD-008 | P1 |
Completed |
Migraine Disorders |
2017-08-22 |
2019-03-21 |
||
| DFN-15-CD-003 | P1 |
Completed |
Healthy Volunteers |
2015-08-14 |
2019-03-22 |
||
| HHC-2017-0224 | P2 |
Completed |
Hyperalgesia|Migraine without Aura|Migraine Disorders|Migraine with Aura |
2019-04-12 |
50% |
2019-04-17 |
|
| DFN-15-CD-010 | P2 |
Completed |
Acute Pain |
2018-08-20 |
50% |
2021-01-25 |
Primary Endpoints |
| DFN-15-CD-002 | P2 |
Completed |
Headache Disorders|Migraine Disorders |
2015-12-01 |
2019-03-20 |
Treatments |
|
| DFN-15-CD-006 | P3 |
Completed |
Migraine Disorders|Headache Disorders |
2017-11-01 |
8% |
2023-01-11 |
Primary Endpoints|Treatments |
| DFN-15-CD-007 | P3 |
Completed |
Migraine Disorders|Headache Disorders |
2017-11-01 |
13% |
2021-11-18 |
Primary Endpoints|Treatments |